Leerink Swann Cuts Aclaris Therapeutics (ACRS) Price Target to $52.00

Aclaris Therapeutics (NASDAQ:ACRS) had its target price decreased by Leerink Swann from $54.00 to $52.00 in a report released on Wednesday morning, MarketBeat reports. Leerink Swann currently has an outperform rating on the biotechnology company’s stock.

Several other analysts also recently commented on ACRS. Cantor Fitzgerald set a $50.00 price objective on shares of Aclaris Therapeutics and gave the company a buy rating in a research report on Monday, March 19th. BidaskClub upgraded shares of Aclaris Therapeutics from a sell rating to a hold rating in a research report on Friday, December 29th. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a sell rating to a hold rating in a research report on Monday, February 19th. Finally, Guggenheim began coverage on shares of Aclaris Therapeutics in a research report on Thursday, February 8th. They set a buy rating and a $53.00 price objective on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $43.50.

How to Become a New Pot Stock Millionaire

Shares of ACRS stock opened at $17.52 on Wednesday. Aclaris Therapeutics has a one year low of $16.75 and a one year high of $33.10.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.80) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $0.80 million. sell-side analysts expect that Aclaris Therapeutics will post -4.29 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC purchased a new position in Aclaris Therapeutics during the third quarter valued at $142,000. Teacher Retirement System of Texas purchased a new position in Aclaris Therapeutics during the fourth quarter valued at $200,000. Trexquant Investment LP purchased a new position in Aclaris Therapeutics during the third quarter valued at $247,000. MetLife Investment Advisors LLC purchased a new position in Aclaris Therapeutics during the fourth quarter valued at $244,000. Finally, Millennium Management LLC purchased a new position in Aclaris Therapeutics during the fourth quarter valued at $291,000. 92.19% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.wkrb13.com/2018/04/01/leerink-swann-cuts-aclaris-therapeutics-acrs-price-target-to-52-00.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply